1
|
Leou K, Mendez D, Horani G, Papagiannakis N, Jiménez Sánchez R, Mazzei D, Mora I, Manickam R, Tourlakopoulos K, Garrido Peñalver JF, Jiménez Medina D, Rodríguez Mulero MD, Annousis K, Laou E, García de Guadiana-Romualdo L, Pantazopoulos I, Kaur K, Chalkias A. Effects of Etomidate on Postintubation Hypotension, Inflammatory Markers, and Mortality in Critically Ill Patients with COVID-19: An International, Multicenter, Retrospective Study. J Intensive Care Med 2023; 38:922-930. [PMID: 37151026 PMCID: PMC10170262 DOI: 10.1177/08850666231173847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 04/17/2023] [Accepted: 04/19/2023] [Indexed: 05/09/2023]
Abstract
OBJECTIVE To evaluate the association of etomidate with postintubation hypotension, inflammation, and mortality in critically ill patients with COVID-19. DESIGN International, multicenter, retrospective study. PARTICIPANTS Critically ill patients hospitalized specifically for COVID-19 from three major academic institutions in the US and Europe. MAIN OUTCOME AND MEASURES Patients were allocated into the etomidate (ET) group or another induction agent (OA) group. The primary outcome was postintubation hypotension. Secondary outcomes included postintubation inflammatory status, in-hospital mortality, and mortality at 30 days. RESULTS 171 patients with a median age of 68 (IQR 58-73) years were included (ET, n = 98; OA, n = 73). Etomidate was associated with lower postintubation mean arterial pressure [74.33 (64-85) mm Hg versus 81.84 (69.75-94.25) mm Hg, p = 0.005] compared to other agents. No statistically significant differences were generally observed in inflammatory markers between the two groups at 7- and 14-days after admission to the intensive care unit. In-hospital mortality [77 (79%) versus 41 (56%), p = 0.003] and mortality at 30-days [78 (80%) versus 43 (59%), p = 0.006] were higher in the ET group. In multivariate logistic regression analysis, only etomidate (p = 0.009) and postintubation mean arterial pressure (p < 0.001) had a statistically significant effect on mortality, in contrast to stress-dose steroids (p = 0.301), after adjusting for creatinine (p = 0.695), blood urea nitrogen (p = 0.153), age (p = 0.055), oxygen saturation of hemoglobin (SpO2) (p = 0.941), and fraction of inspired oxygen (FiO2) (p = 0.712). CONCLUSIONS Administration of a single-bolus dose of etomidate in critically ill patients with COVID-19 is associated with lower postintubation mean arterial pressure and higher in-hospital and 30-day mortality compared to other induction agents.
Collapse
Affiliation(s)
- Konstantinos Leou
- Department of Critical Care Medicine, St. Joseph's University Medical Center, Paterson, NJ, USA
| | - Dianelys Mendez
- Department of Critical Care Medicine, St. Joseph's University Medical Center, Paterson, NJ, USA
| | - George Horani
- Department of Critical Care Medicine, St. Joseph's University Medical Center, Paterson, NJ, USA
| | - Nikolaos Papagiannakis
- First Department of Neurology, Eginition University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | | | - Diana Mazzei
- Department of Critical Care Medicine, St. Joseph's University Medical Center, Paterson, NJ, USA
| | - Isabel Mora
- Department of Critical Care Medicine, St. Joseph's University Medical Center, Paterson, NJ, USA
| | - Rajapriya Manickam
- Department of Critical Care Medicine, St. Joseph's University Medical Center, Paterson, NJ, USA
| | | | | | | | | | | | - Eleni Laou
- Department of Anesthesiology, Agia Sophia Children's Hospital, Athens, Greece
| | | | - Ioannis Pantazopoulos
- Department of Emergency Medicine, Faculty of Medicine, University of Thessaly, Larisa, Greece
| | - Kunwar Kaur
- Department of Critical Care Medicine, St. Joseph's University Medical Center, Paterson, NJ, USA
| | - Athanasios Chalkias
- Department of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece
- Outcomes Research Consortium, Cleveland, OH, USA
| | | |
Collapse
|
2
|
Sozio E, Moore NA, Fabris M, Ripoli A, Rumbolo F, Minieri M, Boverio R, Rodríguez Mulero MD, Lainez-Martinez S, Martínez Martínez M, Calvo D, Gregoriano C, Williams R, Brazzi L, Terrinoni A, Callegari T, Hernández Olivo M, Esteban-Torrella P, Calcerrada I, Bernasconi L, Kidd SP, Sbrana F, Miguens I, Gordon K, Visentini D, Legramante JM, Bassi F, Cortes N, Montrucchio G, Di Lecce VN, Lauritano EC, García de Guadiana-Romualdo L, González del Castillo J, Bernal-Morell E, Andaluz-Ojeda D, Schuetz P, Curcio F, Tascini C, Saeed K. Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin. Respir Res 2022; 23:221. [PMID: 36031619 PMCID: PMC9420187 DOI: 10.1186/s12931-022-02151-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 08/08/2022] [Indexed: 11/13/2022] Open
Abstract
Background Mid-Regional pro-Adrenomedullin (MR-proADM) is an inflammatory biomarker that improves the prognostic assessment of patients with sepsis, septic shock and organ failure. Previous studies of MR-proADM have primarily focussed on bacterial infections. A limited number of small and monocentric studies have examined MR-proADM as a prognostic factor in patients infected with SARS-CoV-2, however there is need for multicenter validation. An evaluation of its utility in predicting need for hospitalisation in viral infections was also performed. Methods An observational retrospective analysis of 1861 patients, with SARS-CoV-2 confirmed by RT-qPCR, from 10 hospitals across Europe was performed. Biomarkers, taken upon presentation to Emergency Departments (ED), clinical scores, patient demographics and outcomes were collected. Multiclass random forest classifier models were generated as well as calculation of area under the curve analysis. The primary endpoint was hospital admission with and without death. Results Patients suitable for safe discharge from Emergency Departments could be identified through an MR-proADM value of ≤ 1.02 nmol/L in combination with a CRP (C-Reactive Protein) of ≤ 20.2 mg/L and age ≤ 64, or in combination with a SOFA (Sequential Organ Failure Assessment) score < 2 if MR-proADM was ≤ 0.83 nmol/L regardless of age. Those at an increased risk of mortality could be identified upon presentation to secondary care with an MR-proADM value of > 0.85 nmol/L, in combination with a SOFA score ≥ 2 and LDH > 720 U/L, or in combination with a CRP > 29.26 mg/L and age ≤ 64, when MR-proADM was > 1.02 nmol/L. Conclusions This international study suggests that for patients presenting to the ED with confirmed SARS-CoV-2 infection, MR-proADM in combination with age and CRP or with the patient’s SOFA score could identify patients at low risk where outpatient treatment may be safe.
Collapse
|
3
|
Martínez-Gascón LE, Ortiz MC, Galindo M, Sanchez JM, Sancho-Rodríguez N, Albaladejo-Otón MD, Rodríguez Mulero MD, Rodriguez F. Role of heme oxygenase in the regulation of the renal hemodynamics in a model of sex-dependent programmed hypertension by maternal diabetes. Am J Physiol Regul Integr Comp Physiol 2022; 322:R181-R191. [PMID: 34984919 DOI: 10.1152/ajpregu.00213.2021] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Accepted: 12/14/2021] [Indexed: 12/11/2022]
Abstract
Intrauterine programming of cardiovascular and renal function occurs in diabetes because of the adverse maternal environment. Heme oxygenase 1 (HO-1) and -2 (HO-2) exert vasodilatory and antioxidant actions, particularly in conditions of elevated HO-1 expression or deficient nitric oxide levels. We evaluated whether the activity of the heme-HO system is differentially regulated by oxidative stress in the female offspring of diabetic mothers, contributing to the improved cardiovascular function in comparison with males. Diabetes was induced in pregnant rats by a single dose of streptozotocin (STZ, 50 mg/kg ip) in late gestation. Three-month-old male offspring from diabetic mothers (MODs) exhibited higher blood pressure (BP), higher renal vascular resistance (RVR), worse endothelium-dependent response to acetylcholine (ACH), and an increased constrictor response to phenylephrine (PHE) compared with those in age-matched female offspring of diabetic mothers (FODs), which were abolished by chronic tempol (1 mM) treatment. In anesthetized animals, stannous mesoporphyrin (SnMP; 40 µmol/kg iv) administration, to inhibit HO activity, increased RVR in FODs and reduced glomerular filtration rate (GFR) in MODs, without altering these parameters in control animals. When compared with MODs, FODs showed lower nitrotirosyne levels and higher HO-1 protein expression in renal homogenates. Indeed, chronic treatment with tempol in MODs prevented elevations in nitrotyrosine levels and the acute renal hemodynamics response to SnMP. Then, maternal diabetes results in sex-specific hypertension and renal alterations associated with oxidative stress mainly in adult male offspring, which are reduced in the female offspring by elevation in HO-1 expression and lower oxidative stress levels.
Collapse
Affiliation(s)
- Lidia E Martínez-Gascón
- Servicio de Análisis Clínicos, Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain
- Instituto Murciano de Investigaciòn Biomédica, IMIB, Murcia, Spain
| | - María Clara Ortiz
- Departamento de Fisiología, Campus de Excelencia Internacional Regional "Campus Mare Nostrum", Universidad de Murcia, Murcia, Spain
- Instituto Murciano de Investigaciòn Biomédica, IMIB, Murcia, Spain
| | - María Galindo
- Servicio de Medicina Intensiva, Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain
- Instituto Murciano de Investigaciòn Biomédica, IMIB, Murcia, Spain
| | | | | | - María Dolores Albaladejo-Otón
- Servicio de Análisis Clínicos, Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain
- Instituto Murciano de Investigaciòn Biomédica, IMIB, Murcia, Spain
| | - María Dolores Rodríguez Mulero
- Servicio de Medicina Intensiva, Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain
- Instituto Murciano de Investigaciòn Biomédica, IMIB, Murcia, Spain
| | - Francisca Rodriguez
- Departamento de Fisiología, Campus de Excelencia Internacional Regional "Campus Mare Nostrum", Universidad de Murcia, Murcia, Spain
- Instituto Murciano de Investigaciòn Biomédica, IMIB, Murcia, Spain
| |
Collapse
|
4
|
García de Guadiana-Romualdo L, Ramos-Arenas V, Rodríguez Mulero MD, Hernández Olivo M, Campos-Rodríguez V, Galindo Martínez M, Ros Braquehais MS, Consuegra-Sánchez L, González Morales M, Albaladejo-Otón MD. Value of hypocalcemia and thromboinflammatory biomarkers for prediction of COVID-19 severity during the second wave: were all the waves the same? Clin Chem Lab Med 2021; 60:e38-e41. [PMID: 34674416 DOI: 10.1515/cclm-2021-0996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Accepted: 10/11/2021] [Indexed: 11/15/2022]
Affiliation(s)
| | - Verónica Ramos-Arenas
- Laboratory Medicine Department, Hospital Universitario Santa Lucía, Cartagena, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
García de Guadiana-Romualdo L, Martínez Martínez M, Rodríguez Mulero MD, Esteban-Torrella P, Hernández Olivo M, Alcaraz García MJ, Campos-Rodríguez V, Sancho-Rodríguez N, Galindo Martínez M, Alcaraz A, Ros Braquehais MS, Báguena Perez-Crespo C, Ramos Arenas V, Tomás Jiménez C, Consuegra-Sánchez L, Conesa-Hernandez A, Piñera-Salmerón P, Bernal-Morell E. Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients. Int J Infect Dis 2021; 111:211-218. [PMID: 34461254 PMCID: PMC8400460 DOI: 10.1016/j.ijid.2021.08.058] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 08/24/2021] [Accepted: 08/24/2021] [Indexed: 12/23/2022] Open
Abstract
Objectives Thromboinflammation, resulting from a complex interaction between thrombocytopathy, coagulopathy, and endotheliopathy, contributes to increased mortality in COVID-19 patients. MR-proADM, as a surrogate of adrenomedullin system disruption, leading to endothelial damage, has been reported as a promising biomarker for short-term prognosis. We evaluated the role of MR-proADM in the mid-term mortality in COVID-19 patients. Methods A prospective, observational study enrolling COVID-19 patients from August to October 2020. A blood sample for laboratory test analysis was drawn on arrival in the emergency department. The primary endpoint was 90-day mortality. The area under the curve (AUC) and Cox regression analyses were used to assess discriminatory ability and association with the endpoint. Results A total of 359 patients were enrolled, and the 90-day mortality rate was 8.9%. ROC AUC for MR-proADM predicting 90-day mortality was 0.832. An optimal cutoff of 0.80 nmol/L showed a sensitivity of 96.9% and a specificity of 58.4%, with a negative predictive value of 99.5%. Circulating MR-proADM levels (inverse transformed), after adjusting by a propensity score including eleven potential confounders, were an independent predictor of 90-day mortality (HR: 0.162 [95% CI: 0.043-0.480]) Conclusions Our data confirm that MR-proADM has a role in the mid-term prognosis of COVID-19 patients and might assist physicians with risk stratification.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Antonia Alcaraz
- Infectious Disease Unit, Hospital General Universitario Reina Sofía, Murcia, Spain
| | | | | | - Verónica Ramos Arenas
- Laboratory Medicine Department, Hospital Universitario Santa Lucía, Cartagena, Spain
| | | | | | | | | | - Enrique Bernal-Morell
- Infectious Disease Unit, Hospital General Universitario Reina Sofía, Murcia, Spain; Instituto Murciano de Investigación Biosanitaria (IMIB).
| |
Collapse
|
6
|
García de Guadiana-Romualdo L, Calvo Nieves MD, Rodríguez Mulero MD, Calcerrada Alises I, Hernández Olivo M, Trapiello Fernández W, González Morales M, Bolado Jiménez C, Albaladejo-Otón MD, Fernández Ovalle H, Conesa Hernández A, Azpeleta Manrique E, Consuegra-Sánchez L, Nogales Martín L, Conesa Zamora P, Andaluz-Ojeda D. MR-proADM as marker of endotheliitis predicts COVID-19 severity. Eur J Clin Invest 2021; 51:e13511. [PMID: 33569769 PMCID: PMC7995076 DOI: 10.1111/eci.13511] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2021] [Accepted: 02/08/2021] [Indexed: 12/15/2022]
Abstract
BACKGROUND Early identification of patients at high risk of progression to severe COVID-19 constituted an unsolved challenge. Although growing evidence demonstrates a direct association between endotheliitis and severe COVID-19, the role of endothelial damage biomarkers has been scarcely studied. We investigated the relationship between circulating mid-regional proadrenomedullin (MR-proADM) levels, a biomarker of endothelial dysfunction, and prognosis of SARS-CoV-2-infected patients. METHODS Prospective observational study enrolling adult patients with confirmed COVID-19. On admission to emergency department, a blood sample was drawn for laboratory test analysis. Primary and secondary endpoints were 28-day all-cause mortality and severe COVID-19 progression. Area under the curve (AUC) and multivariate regression analysis were employed to assess the association of the biomarker with the established endpoints. RESULTS A total of 99 patients were enrolled. During hospitalization, 25 (25.3%) cases progressed to severe disease and the 28-day mortality rate was of 14.1%. MR-proADM showed the highest AUC to predict 28-day mortality (0.905; [CI] 95%: 0.829-0.955; P < .001) and progression to severe disease (0.829; [CI] 95%: 0.740-0.897; P < .001), respectively. MR-proADM plasma levels above optimal cut-off (1.01 nmol/L) showed the strongest independent association with 28-day mortality risk (hazard ratio [HR]: 10.470, 95% CI: 2.066-53.049; P < .005) and with progression to severe disease (HR: 6.803, 95% CI: 1.458-31.750; P = .015). CONCLUSION Mid-regional proadrenomedullin was the biomarker with highest performance for prognosis of death and progression to severe disease in COVID-19 patients and represents a promising predictor for both outcomes, which might constitute a potential tool in the assessment of prognosis in early stages of this disease.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Hilda Fernández Ovalle
- Primary Care Valladolid West Area, Centro de Salud Parque Alameda-Covaresa, Valladolid, Spain.,Endocrinology and Clinical Nutrition Research Center (ECNRC), Universidad de Valladolid, Valladolid, Spain
| | | | | | | | - Leonor Nogales Martín
- Intensive Care Medicine Department, Hospital Clínico Universitario, Valladolid, Spain
| | - Pablo Conesa Zamora
- Laboratory Medicine Department, Hospital Universitario Santa Lucía, Cartagena, Spain
| | - David Andaluz-Ojeda
- Intensive Care Medicine Department, Hospital Clínico Universitario, Valladolid, Spain
| |
Collapse
|
7
|
Luis García de Guadiana Romualdo, Mulero MDR, Olivo MH, Rojas CR, Arenas VR, Morales MG, Abellán AB, Conesa-Zamora P, García-García J, Hernández AC, Morell-García D, Dolores Albaladejo-Otón M, Consuegra-Sánchez L. Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: A case series. J Infect 2021; 82:e40-e42. [PMID: 32795482 PMCID: PMC7419246 DOI: 10.1016/j.jinf.2020.08.010] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Accepted: 08/09/2020] [Indexed: 12/31/2022]
Affiliation(s)
- Luis García de Guadiana Romualdo
- Medicine Laboratory Department, Hospital Universitario Santa Lucía, Cartagena, Spain. C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain.
| | - María Dolores Rodríguez Mulero
- Intensive Care Unit, Hospital Universitario Santa Lucía, Cartagena, Spain. C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain
| | - Marta Hernández Olivo
- Pneumology Department, Hospital Universitario Santa Lucía, Cartagena, Spain C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain
| | - Carlos Rodríguez Rojas
- Medicine Laboratory Department, Hospital Universitario Santa Lucía, Cartagena, Spain. C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain
| | - Verónica Ramos Arenas
- Medicine Laboratory Department, Hospital Universitario Santa Lucía, Cartagena, Spain. C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain
| | - Mercedes González Morales
- Medicine Laboratory Department, Hospital Universitario Santa Lucía, Cartagena, Spain. C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain
| | - Ana Blazquez Abellán
- Microbiology and Parasitology Department, Hospital Universitario Santa Lucía, Cartagena, Spain. C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain
| | - Pablo Conesa-Zamora
- Medicine Laboratory Department, Hospital Universitario Santa Lucía, Cartagena, Spain. C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain
| | - Josefina García-García
- Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Santa Lucía, Cartagena, Spain. C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain
| | - Andrés Conesa Hernández
- Emergency Department ,Hospital Universitario Santa Lucía, Cartagena, Spain. C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain
| | - Daniel Morell-García
- Medicine Laboratory Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain. Carretera de Valldemossa 79, Palma 07120, Spain
| | - María Dolores Albaladejo-Otón
- Medicine Laboratory Department, Hospital Universitario Santa Lucía, Cartagena, Spain. C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain
| | - Luciano Consuegra-Sánchez
- Cardiology Department, Hospital Universitario Santa Lucía, Cartagena, Spain C/ Mezquita, s/n, Paraje Los Arcos, Cartagena, Santa Lucía 30202, Spain
| |
Collapse
|